- Previous Close
11.01 - Open
11.00 - Bid 10.77 x 400
- Ask 10.87 x 200
- Day's Range
10.60 - 11.01 - 52 Week Range
7.51 - 18.93 - Volume
75,123 - Avg. Volume
140,865 - Market Cap (intraday)
280.429M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-1.94 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.20
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
www.avitamedical.comRecent News: RCEL
View More
Performance Overview: RCEL
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RCEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RCEL
View MoreValuation Measures
Market Cap
286.15M
Enterprise Value
277.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.20
Price/Book (mrq)
11.97
Enterprise Value/Revenue
5.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-92.04%
Return on Assets (ttm)
-38.98%
Return on Equity (ttm)
-107.66%
Revenue (ttm)
54.14M
Net Income Avi to Common (ttm)
-49.83M
Diluted EPS (ttm)
-1.94
Balance Sheet and Cash Flow
Total Cash (mrq)
54.06M
Total Debt/Equity (mrq)
188.54%
Levered Free Cash Flow (ttm)
-36.56M
Research Analysis: RCEL
View MoreCompany Insights: RCEL
RCEL does not have Company Insights